3//SEC Filing
BP Directors, LP 3
Accession 0001813316-20-000001
CIK 0001763950other
Filed
Jun 9, 8:00 PM ET
Accepted
Jun 10, 7:17 PM ET
Size
32.9 KB
Accession
0001813316-20-000001
Insider Transaction Report
Form 3
Kreis Leslie W.
10% Owner
Holdings
- 64,734(indirect: By Bios Fund II, LP)
Common Stock
- 211,456(indirect: By Bios Fund II QP, LP)
Common Stock
- 28,308(indirect: By Bios Fund II NT, LP)
Common Stock
- (indirect: By Bios Fund I, LP)
Series A Warrants
Exercise: $3.13From: 2017-03-17Exp: 2022-03-17→ Common Stock (60,431 underlying) - (indirect: By Bios Fund I QP, LP)
Series A Preferred Stock
→ Common Stock (294,557 underlying) - (indirect: By Bios Fund I QP, LP)
Series A Warrants
Exercise: $3.13From: 2017-03-17Exp: 2022-03-17→ Common Stock (35,346 underlying) - (indirect: By Bios Fund II, LP)
Series A Preferred Stock
→ Common Stock (139,989 underlying) - (indirect: By Bios Fund II, LP)
Series A Warrants
Exercise: $3.13From: 2019-03-07Exp: 2024-03-07→ Common Stock (16,799 underlying) - (indirect: By Bios Fund II QP, LP)
Series A Preferred Stock
→ Common Stock (457,282 underlying) - (indirect: By Bios Fund II NT, LP)
Series A Preferred Stock
→ Common Stock (61,214 underlying) - (indirect: By BP Directors, LP)
Stock Options
Exercise: $1.03From: 2018-12-17Exp: 2028-12-16→ Common Stock (32,538 underlying) - (indirect: By Bios Fund I, LP)
Series A Preferred Stock
→ Common Stock (503,606 underlying) - (indirect: By Bios Fund II QP, LP)
Series A Warrants
Exercise: $3.13From: 2019-03-07Exp: 2024-03-07→ Common Stock (54,872 underlying) - (indirect: By Bios Fund II NT, LP)
Series A Warrants
Exercise: $3.13From: 2019-03-07Exp: 2024-03-07→ Common Stock (7,346 underlying)
Footnotes (10)
- [F1]In connection with the Issuer's initial public offering ("IPO"), the Issuer intends to effect a 1.74-for-1 stock split on its outstanding common stock, which will become effective immediately prior to the closing of the Issuer's IPO ("Stock Split"). The share amounts and the price reflect the anticipated Stock Split.
- [F10]For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
- [F2]Bios Fund I, LP ("Bios Fund I") is a direct beneficial owner of: (i) 289,429 shares of the Issuer's Series A Preferred Stock, which have no expiration date and will automatically convert into 503,606 shares of common stock immediately prior to the closing of the Issuer's IPO, and (ii) warrants to purchase up to 34,731 shares of the Issuer's Series A Preferred Stock; provided, that upon the closing of the Issuer's IPO, such warrants will be amended to represent a right to purchase up to 60,431 shares of common stock at $3.13 per share.
- [F3]Bios Fund I QP, LP ("Bios Fund I QP") is a direct beneficial owner of: (i) 169,286 shares of the Issuer's Series A Preferred Stock, which have no expiration date and will automatically convert into 294,557 shares of common stock immediately prior to the closing of the Issuer's IPO, and (ii) warrants to purchase up to 20,314 shares of the Issuer's Series A Preferred Stock; provided, that upon the closing of the Issuer's IPO, such warrants will be amended to represent a right to purchase up to 35,346 shares of common stock at $3.13 per share.
- [F4]Bios Fund II, LP ("Bios Fund II") is a direct beneficial owner of: (i) 64,734 shares of common stock, (ii) 80,454 shares of the Issuer's Series A Preferred Stock, which have no expiration date and will automatically convert into 139,989 shares of common stock immediately prior to the closing of the Issuer's IPO, and (iii) warrants to purchase up to 9,655 shares of the Issuer's Series A Preferred Stock; provided, that upon the closing of the Issuer's IPO, such warrants will be amended to represent a right to purchase up to 16,799 shares of common stock at $3.13 per share.
- [F5]Bios Fund II QP, LP ("Bios Fund II QP") is a direct beneficial owner of: (i) 211,456 shares of common stock, (ii) 262,806 shares of the Issuer's Series A Preferred Stock, which have no expiration date and will automatically convert to 457,282 shares of common stock immediately prior to the closing of the Issuer's IPO, and (iii) warrants to purchase up to 31,536 shares of the Issuer's Series A Preferred Stock; provided, that upon the closing of the Issuer's IPO, such warrants will be amended to represent a right to purchase up to 54,872 shares of common stock at $3.13 per share.
- [F6]Bios Fund II NT, LP ("Bios Fund II NT") is a direct beneficial owner of: (i) 28,308 shares of common stock, (ii) 35,181 shares of the Issuer's Series A Preferred Stock, which have no expiration date and will automatically convert to 61,214 shares of common stock immediately prior to the closing of the Issuer's IPO, and (iii) warrants to purchase up to 4,222 shares of Series A Preferred Stock; provided, that upon the closing of the Issuer's IPO, such warrants will be amended to represent a right to purchase up to 7,346 shares of common stock at $3.13 per share.
- [F7]BP Directors, LP ("Bios Directors") is a direct beneficial owner of options to purchase 32,538 shares of common stock exercisable within 60 days.
- [F8]Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Mr. Kreis, is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management.
- [F9]Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
Documents
Issuer
Lantern Pharma Inc.
CIK 0001763950
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001813311
Filing Metadata
- Form type
- 3
- Filed
- Jun 9, 8:00 PM ET
- Accepted
- Jun 10, 7:17 PM ET
- Size
- 32.9 KB